Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Etelcalcetide in Secondary Hyperparathyroidism on Hemodialysis
NCT02102204Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2014
- Primary completion
- Nov 2016
- Modality
- Peptides, Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Started Mar 2014; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02102204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102204.